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Abstract
Background Annually 2.7 million individuals are offered screening for diabetic retinopathy (DR) in England. Spectral-
Domain Optical Coherence Tomography (SD-OCT) has the potential to relieve pressure on NHS services by correctly
identifying patients who are screen positive for maculopathy on two-dimensional photography without evidence of clinically
signiﬁcant macular oedema (CSMO), limiting the number of referrals to hospitals. We aim to assess whether the addition of
SDOCT imaging in digital surveillance clinics is a cost-effective intervention relative to hospital eye service (HES) follow-
up.
Methods We used patient-level data from the Gloucestershire Diabetic Eye Screening Service linked to the local digital
surveillance programme and HES between 2012 and 2015. A model was used to simulate the progression of individuals with
background diabetic retinopathy (R1) and diabetic maculopathy (M1) following DR screening across the clinic pathways
over 12 months.
Results Between January 2012 and December 2014, 696 people undergoing DR screening were found to have screen-
positive maculopathy in at least one eye for the ﬁrst time, with a total of 766 eyes identiﬁed as having R1M1. The mean
annual cost of assessing and surveillance through the SD-OCT clinic pathway was £101 (95% CI: 91–139) as compared with
£177 (95%CI: 164–219) under the HES pathway. Surveillance under an SD-OCT clinic generated cost savings of £76 (95%
CI: 70–81) per patient.
Conclusions Our analysis shows that SD-OCT surveillance of patients diagnosed as R1M1 at DR screening is not only cost-
effective but generates considerable cost savings.
Introduction
Diabetes places a great economic burden on society owing
to its high prevalence and increased health-care expendi-
tures and lost productivity. Although the treatment of dia-
betes on its own is costly, its complications are the major
contributors to health-care costs [1]. Among the main
diabetes-related complications is diabetic retinopathy (DR),
which is an important cause of blindness in the working age
population in the UK [2]. It is possible to treat sight
threatening DR effectively [3, 4] and cost-effectively [5]
and screening using retinal photography has been shown to
be cost-effective [6]. A common cause of sight-threatening
retinopathy is diabetic macular oedema [7], which can be
treated effectively by either macular laser treatment or anti-
vascular endothelial growth factor (VEGF) injections [8].
However, treatment is only recommended for patients with
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clinically signiﬁcant macular oedema (CSMO), with non-
CSMO patients deriving little additional beneﬁt from
treatment [4].
In 2003, the NHS Diabetic Eye Screening Programme
(NDESP) was introduced in England which uses annual
digital photography with pupil dilation [9, 10]. Until 2015,
NDESP recommended all screen-positive patients identiﬁed
with mild non-proliferative DR and maculopathy (R1M1),
moderate/severe non/pre-proliferative DR (R2M0, R2M1),
or proliferative retinopathy (R3M0, R3M1) be referred to a
hospital eye services (HES) for treatment assessment.
However, given the limitations of two-dimensional digital
photographic retinal screening for maculopathy, less than a
quarter of referred M1 patients were found to have CSMO
in need of treatment [11].
In January 2015, digital surveillance was included in the
standard NDESP pathway for annual screening with a
statement in the annual service speciﬁcation “the provider
shall: refer people with diabetes to digital surveillance
clinics that, in the opinion of the Clinical Lead, need more
frequent review and do not require referral to the HES. This
should be done against local protocols based on best evi-
dence and NDESP guidance, using appropriate technology.
Surveillance clinics may interface with OCT assessment
where this has been agreed with commissioners of hospital
eye services” and a pathway overview diagram which is
unchanged in current documents [12, 13]. The digital sur-
veillance pathway standards [14] were updated in March
2018 to include a new standard (DES-PS-5) to ensure those
in digital surveillance are seen within an appropriate time
frame. No guidance has been given on grading criteria used
within digital surveillance or on the use of OCT which is
currently considered ‘optional’.
In June 2017, 2.7 million people were offered DR
screening with 2.25 million uptake (82.2%) [15], with an
epidemic posing an ever-growing strain on the screening
programme and resources in the wider NHS. One way to
relieve pressure on NHS services would be to improve the
speciﬁcity of the current screening programme. Spectral
domain optical coherence tomography (OCT) is an imaging
technique that interprets reﬂected optical waves from a
depth in the retina of 2–3 mm to produce three-dimensional
images with the potential to correctly identify patients
without evidence of any oedema in the macular area or
CSMO, therefore limiting the number of referrals to hos-
pitals and improving the speciﬁcity of the current screening
programme [16].
Although SD-OCT imaging has been shown to be a
useful adjunct in surveillance clinics for screen-positive
diabetic maculopathy [16], questions remain about its cost-
effectiveness in the clinical setting given its high imple-
mentation costs. Using detailed data from the Gloucester-
shire SD-OCT clinic surveillance programme, we aim to
assess whether the addition of SD-OCT imaging surveil-
lance in a community setting following digital retinal pho-
tography is a cost-effective intervention when screening for
CSMO relative to hospital eye service assessment and
follow-up.
Methods
Participants
We used patient-level data from the Gloucestershire
Diabetic Eye Screening Service linked to the local digital
surveillance programme and HES covering the period
between 1st January 2009 and 31st December 2015. An
anonymised cohort dataset of individuals with incident
R1M1 in one eye as detected by GDESP between 1st Jan-
uary 2012 and 31st December 2014 was analysed. To
ensure that only incident R1M1 cases were considered in
our analysis, we excluded patients with previous history of
R1M1 (that is, those individuals screened as R1M1 between
January 2009 and December 2011). HES and SD-OCT
clinic surveillance data were analysed up to 31st December
2015, allowing for at least a full year of follow-up for all
incident R1M1 cases. These data included basic demo-
graphics, DR screening encounters, grading and referral
outcomes, SDOCT clinic grading and referral outcomes,
and HES grading, referral and treatment outcomes from two
sources:
a. Gloucestershire Diabetic Retinopathy Eye Screening
Programme (GDESP)
i. A diabetes register for Gloucestershire provided by a
regularly updated and collated data download from
each Gloucestershire primary care General Practice.
ii. Every DR screening encounter, grade, outcome and
referral recorded in detail since 1998 and GDESP
operational pathways and data requirements managed
in accordance with National Screening Programme
speciﬁcations and standards.
a. Gloucestershire Hospital Eye Service (HES)
i. The HES data consists of an electronic medical record
(EMR) for every patient attending an HES appoint-
ment;
ii. Patient demographic Electronic Medical Record
(EMR) is managed by an electronic interface with
Gloucestershire Patient Administration System (PAS)
and clinical episodes are recorded, by medical and
allied health professional staff at the time of a patient
encounter.
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Interventions under study
We estimated the cost-effectiveness of two pathways of
surveillance for individuals with incident R1M1 grading
detected in the diabetic screening programme:
Technician led digital surveillance clinic including SD-
OCT in a community setting
Ophthalmologist led HES clinic assessment and follow-
up
At the time of the analysis, the English National
Screening Programme recommended annual screening for
all patients with diabetes. The technician led digital sur-
veillance pathway consisted of two ﬁeld mydriatic digital
photography (macular and disc ﬁelds) followed by a
macular SD-OCT using a Topcon OCT 2000. For the HES
clinical surveillance pathway, this consisted of a slit lamp
biomicroscopy examination by an ophthalmologist and a
macular SD-OCT using one of three SD-OCT machines
used within the HES (Heidelberg Spectralis, Zeiss Cirrhus
or the Topcon OCT 2000). Patients attending HES who did
not need treatment were followed up in a similar fashion to
that observed in the SD-OCT clinic surveillance programme
in a community setting, with the exception that patients
would continue to be assessed in HES. The comparison of
the two pathways is shown in Online Appendix Figure A1.
Grading criteria
The grading criteria used for retinopathy (R) and maculo-
pathy (M) grades in the NHS Diabetic Eye Screening
Programme are published [17] by NDESP. Online Appen-
dix Table A1 reports the grading criteria and assessment of
image quality for the SD-OCT images.
Model structure
A decision analytic model was developed to evaluate the
impact of the two pathways of surveillance under evalua-
tion. Given the clinic pathways and the 1 year of time
horizon used in the analysis, the most appropriate model
was judged to be a decision tree which was developed in
Excel (Microsoft, Redmond, WA). Model structure and
assumptions were informed by what was known about
diabetic retinopathy, the clinic pathways of R1M1 indivi-
duals and discussions with clinical experts and statisticians
involved in the project. The model was used to simulate the
progression of R1M1 individuals following DR screening
across the clinic pathways over 12 months (Fig. 1). Nearly
all individuals who were screen positive for R1M1 were
referred to SD-OCT digital surveillance clinics with a very
small number referred to HES. Hence, the R1M1 population
was ﬁrst divided into those that attended the SD-OCT/HES
clinic appointments and those that did not.
Of those attending SD-OCT clinic or HES, we further
divided the R1M1 population according to the grading in
the other eye at screening: R0/R1, R1M1 or R2-R3. Con-
ditional on the grading in the other eye, we classiﬁed the
R1M1 at screening according to their possible grading at
SD-OCT/HES clinic appointments: R0M0, R1M0, R1M1
and R2-R3. We then further divided these subgroups
according to their SD-OCT results: negative, borderline and
positive. Conditional on the DR/OCT results, the indivi-
duals could be referred back to DR screening, to further
surveillance (at the SD-OCT clinic or HES) or directly to
HES for possible treatment of maculopathy. If referred for
further surveillance, the frequency of surveillance could be:
4 months or less, 6 months, 9 months or 12 months. If
referred to HES for possible maculopathy treatment, indi-
viduals might or might not receive treatment (VEGF
injection or laser). Given the use of the same equipment in
the digital surveillance pathway and the hospital eye ser-
vices (SD-OCT) and similar levels of DR/OCT grading
expertise grading in both settings, we assumed that the
grading, outcomes and frequency of referral would be
identical in both models.
Costs
Following NICE recommendations, the perspective for the
analysis was that of the UK NHS and the price year was
2015/16. Costs included: SD-OCT clinic surveillance
appointment cost in a community setting; HES outpatient
appointment costs; capital cost of SD-OCT in a hospital
9 months
R1M1 
at clinic 
OCT negative 
OCT borderline 
OCT positive 
Surveillance
HES (for treatment)
DR screening programme
4 months or less
6 months
12 months
Injection
Laser
None
Fig. 1 Model structure for individuals with R1M1 grading at SDOCT
clinic appointment. The same model structure applies for R0M0,
R1M0 and R2-R3 grading at SDOCT clinic appointment. The circles
denote ‘chance’ nodes where branches meet (representing likely
events) that set out the probability of an event occurring or not (e.g.,
OCT negative/borderline or positive given R1M1 grading at SDOCT
clinic). The probabilities of events must always sum up to one at any
given node. Costs were assigned to each branch including the end of
the branch to value the resource use associated with each possible
model pathway. These costs are combined with branch probabilities
and the tree is ‘rolled back’ so that mean cost of the intervention can be
estimated
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setting, and hospital-based treatment costs for CSMO
(VEGF injection and laser) (see Online Appendix
Table A2). The costs of SD-OCT surveillance clinics were
obtained from a recent report evaluating community relative
to hospital eye service follow-up for patients with age-
related macular degeneration. [18] These authors deter-
mined the costs of monitoring review in a community set-
tings (£51.82 in 2013/14 prices) as well as the costs of SD-
OCT equipment by review (£22.99 in 2013/14 prices).
Outpatient consultation costs for ophthalmology were
obtained from NHS Reference Costs 2015/16. [19] We
costed the ﬁrst outpatient appointment following DR
screening as a consultant led ﬁrst appointment and the
remaining appointments as consultant-led follow-up
appointments. Under the HES pathway, we added the OCT
equipment costs to outpatient appointment costs. The
annual costs associated with laser or VEGF injections for
the treatment of CSMO were obtained from patient-level
data from patients attending DR screening in Gloucester-
shire. [20]
Statistical analysis
We converted the Gloucestershire patient-level dataset into
eye-level data so that we could follow the clinical pathway,
grading and outcomes for the eye graded as R1M1 at
screening over 12 months. These data were used to estimate
the grade at screening in the other eye (R0-R1M0, R1M1
and R2-R3), the uptake of surveillance, the grading at
community or HES surveillance clinic, and the number of
surveillance appointments attended during the 12 months
following initial screening. For example, the uptake rate of
the surveillance clinics (community or HES-based) was
determined by dividing the number of attenders, within
12 months of screening, out of all those referred at
screening for HES or SD-OCT surveillance. We also used
three regression models to estimate:
1. Probability of each referral outcome (i.e., referral back
to DR screening, SD-OCT surveillance in a commu-
nity or HES setting, HES direct referral for possible
treatment of maculopathy) following the SD-OCT
surveillance clinic appointment (multinomial logit);
2. Probability of the frequency of surveillance (i.e.,
4 months or less, 6 months, 9 months or 12 months)
following SD-OCT surveillance clinic appointment
(ordered logit);
3. Probability of receiving treatment for CSMO (VEGF
injection or laser).
We examined the following predictors: SD-OCT result
(positive, borderline, negative), grading at surveillance
clinic (R0M0, R1M0, R1M1), screening grade in other eye
(R0-R1, R1M1) and other ocular conditions (e.g., macular
degeneration). A predictor was deemed to be statistically
signiﬁcant if p < 0.05. Model ﬁt was assessed using Pregi-
bon’s link test. All analyses were performed using STATA
version 14 (StataCorp, College Station, TX).
Cost-effectiveness analysis
Following the assumption that the clinic pathways under
evaluation would result in the same patient grading results,
OCT results, and subsequent referrals for treatment or fur-
ther surveillance, the quality of life of the R1M1 individuals
was assumed to be the same. As a result, we estimated the
incremental costs associated with surveillance in an SD-
OCT clinic pathway relative to HES. Probabilistic sensi-
tivity analysis (PSA) was performed where distributions
were used to represent the uncertainty in the model inputs
[21]. Furthermore, to capture the uncertainty and correla-
tions between the three regression models we re-estimated
the same set of models for each of the 1000 bootstraps (with
replacement) of the sample dataset and saved the coefﬁ-
cients from the three regression models.
Scenario analysis
We explored the impact of the scenario that once eyes were
assessed at HES for the ﬁrst time after diagnosis of R1M1 at
screening they would no longer require further surveillance.
We also explored no further surveillance for SD-OCT
negative results if clinic grading was R0M0 or R1M0 in
both pathways.
Results
Gloucester cohort study and model inputs
Number of eyes identiﬁed with R1M1 at screening
Between January 2012 and December 2014, 696 people
with diabetes screened for diabetic retinopathy were found
to be screen positive for maculopathy (M1) in at least one
eye for the ﬁrst time. Of these, 622 (89%) had a diagnosis of
R1M1 in one eye, 4 had R1M1 in one eye and moderate to
proliferative retinopathy R2M1 in the other eye (1%) and 70
(10%) had R1M1 in both eyes (Table 1), with a total of 766
eyes diagnosed as having R1M1.
Eye referral once identiﬁed with R1M1 at screening
All 696 individuals identiﬁed as having R1M1 at screening
were referred to either HES or SD-OCT clinics, with 37
(5%) failing to attend their appointments within the ﬁrst
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year after screening (Fig. 2). Of the remaining 659 patients,
652 (99%) were initially assessed at a digital surveillance
clinic with SD-OCT after their screening episode and 7
(1%) were assessed at HES.
SD-OCT grading of eyes identiﬁed with R1M1 at screening
Table 2 presents the results of the grading at the SD-OCT
clinic, stratiﬁed by screen grade for the other eye, for the
652 patients attending an SD-OCT clinic because of diag-
nosis of R1M1 at screening.
Of the 652 patients attending SD-OCT clinic, 13 (2%)
patients had missing or incomplete data (e.g., absence of an
OCT result). For the remaining 639 patients, 572 (81%)
were diagnosed with R1M1 at screening the other eye was
diagnosed as R0/1M0 at screen (Table 2). At the ﬁrst SD-
OCT clinic visit, 171 (30%) of R1M1 patients at screening
and with R0/1M0 in the other eye were found to be R1M1
but with an SD-OCT negative result, and 54 (9%) as R1M1
with a positive result. There were 65 patients (10%) with
R1M1 in both eyes at screening (that is. 130 eyes in total).
Of these patients, 2 (6%) had SD-OCT positive results in
both eyes and 12 (18%) had SD-OCT positive results in one
eye. Only two patients diagnosed as having R1M1 at
screening were diagnosed with R2/3 in the other eye.
Overall, for the 639 patients, irrespective of diabetic
Table 1 Baseline characteristics of patients identiﬁed with diabetic
maculopathy at screening
n (%) (n= 696)
Gender
Males 440 (57)
Females 326 (43)
Age range, years
<21 6 (1)
21 to 30 19 (2)
31 to 40 37 (5)
41 to 50 97 (13)
51 to 60 142 (19)
61 to 70 168 (23)
71 to 80 178 (23)
81 to 90 113 (15)
≥91 6 (1)
Diabetes type
Type 1 102 (14)
Type 2 846 (86)
Duration diabetes, mean years (SD) 13 (9)
Screening grade
Background retinopathy and DM in one eye
R1M1/R0M0 181 (26)
R1M1/R1M0 441 (63)
R2M0/R1M1 2 (<1)
R2M1/R1M1 1 (<1)
R3M1/R1M1 1 (<1)
Background retinopathy and DM in both eyes
R1M1/R1M1 70 (10)
Patients with R1M1 in at least one 
eye referred to HES or OCT 
clinics 
n=696 
Not attending HES or OCT clinics 
n=37 
Assessed in OCT clinic 
n=652 
Assessed in HES 
n=7 
Fig. 2 Patient pathway after diagnosis of incident background retino-
pathy and maculopathy at screening
Table 2 Eye grading at the SDOCT clinic, stratiﬁed by screen grade of
the other eyea
Digital surveillance
grade
Screen grade of
other eye
R0/1M0 n (%)
R1M1
n (%)
R2/3MX
n (%)
R0M0
OCT negative 53 (10) 8 (6) 0
OCT borderline 6 (1) 0 0
OCT positive 6 (1) 0 0
R1M0
OCT negative 156 (27) 37 (28) 0
OCT borderline 25 (4) 6 (5) 0
OCT positive 13 (2) 3 (2) 0
R1M1
OCT negative 171 (30) 45 (35) 1 (50)
OCT borderline 77 (13) 18 (14) 0
OCT positive 54 (9) 13 (10) 1 (50)
R2/3MX
OCT negative 4 (1) 0 0
OCT borderline 2 (<1) 0 0
OCT positive 1 (<1) 0 0
RUMX
OCT negative 2 (<1) 0 0
OCT borderline 1 (<1) 0 0
OCT positive 1 (<1) 0 0
Total 572 (100) 130 (100)* 2 (100)
aResults per eye conditional on the screening grade of the other eye.
MX: M0 or M1; RU: unknown retinopathy grade. For the 65 patients
who were identiﬁed as having R1M1 in both eyes and had recorded
SDOCT results the data has been reported for both eyes
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retinopathy grading in the SD-OCT clinic, a total of 90
(14%) patients tested SD-OCT positive and 477 (66%)
tested negative.
Referral outcome following SD-OCT grading
For the 639 patients with recorded SD-OCT results, out-
come data were missing in 11 (2%) patients. For the
remaining 628 patients, 118 (19%) were returned to the DR
annual screening programme, 412 (66%) continued under
SD-OCT clinic surveillance, and 98 (16%) were referred to
HES. Patients with SD-OCT positive results were sig-
niﬁcantly more likely to be referred to HES after controlling
for SD-OCT clinic grading of the eye and the screen
grading of the other eye (see Online Appendix Table A3).
Of the 412 patients under continued SD-OCT clinic
surveillance, 4 (<1%) were followed up in SD-OCT clinic
surveillance between 1 and 3 months, 174 (42%) every
6 months, 72 (17%) every 9 months and 162 (39%) were
referred to annual SD-OCT clinic surveillance. Patients with
SD-OCT negative results in one eye were signiﬁcantly more
likely to have longer surveillance intervals than those with
positive or borderline results after controlling for SD-OCT
clinic grading of the eye and the screen grading of the other
eye (see Online Appendix Table A4).
Including the initial SD-OCT clinic visit, the mean
number of SD-OCT clinic visits for patients who were
referred to SD-OCT clinic surveillance every 3, 6, 9 and
12 months was, respectively: 2.00 (S.D. 1.15); 1.95 (S.D.
0.44); 1.59 (S.D. 0.49); and 1.05 (S.D. 0.24) visits.
Treatment for CSMO
Of the 639 patients assessed at the SD-OCT clinic for
suspected R1M1 and with SD-OCT results, 18 (3%)
received treatment with laser or VEGF injection. Of these, 7
(39%) received VEGF injection and 11 (61%) received laser
treatment. Results of the logistic regression (Online
Appendix Table A5) showed that a SD-OCT positive result
was the only signiﬁcant predictor of increased likelihood of
treatment (odds ratio 36, 95% CI: 10–126). Therefore, the
probability of treatment given a SD-OCT positive result was
16%.
Cost comparison between SD-OCT and HES
surveillance
Online Appendix Table A2 reports the model inputs used to
compare SD-OCT and HES surveillance pathways. The
mean annual cost of assessing and surveillance of an eye
identiﬁed as R1M1 at DR screening through the SD-OCT
clinic pathway was £101 (95% CI: 91–139) per patient
(Table 3). Results showed that the mean annual cost of
assessing and surveillance of patient with at least one eye
diagnosed as R1M1 at DR screening through the HES
pathway was £177 (95% CI: 164–219) per patient.
As a result, the mean annual cost saving per patient
with one identiﬁed as R1M1 in the DR screening pro-
gramme and surveilled in the SD-OCT digital surveillance
pathway as opposed to a HES pathway was £76 (95% CI:
70–81), with these savings arising from less patients
without maculopathy or negative SD-OCT results being
referred to HES. Even if, under the HES pathway, a
patient with R1M1 was assessed at HES for the ﬁrst time
after diagnosis of R1M1 at screening and no longer
require surveillance, the SD-OCT clinic pathway still
generated savings of £41 (95% CI: £37–£46) per eye
assessed. Finally, assuming that there was no further
surveillance for SD-OCT negative results if the clinic
grading was R0M0 or R1M0 generated savings of £74
(95%CI: £67–£79) (Table 3).
Discussion
Diabetic retinopathy screening is nationally mandated and
has been shown to be cost-effective compared with no
screening [22–24]. There is also a clear understanding about
the appropriateness of different screening intervals for
patients at differing risks of developing sight threatening
DR [20]. In addition, studies have suggested that including
an SD-OCT digital surveillance pathway could improve the
overall efﬁciency of the DR screening programme [16], and
its cost-effectiveness [25].
This study, based on 652 patients and over 700 eyes
diagnosed as screen positive for maculopathy with back-
ground DR, and referred almost entirely for surveillance in
an SD-OCT clinic, provides further evidence that surveil-
lance of these patients in an SD-OCT clinic is not only cost-
Table 3 Cost-effectiveness results of SDOCT digital surveillance in a
community setting vs. HES (2015/16 prices)
Base case
(£)
Scenario 1
(£)a
Scenario 2
(£)b
SDOCT surveillance
Cost per patient Mean= 101 101 99
95% CI= 91–139 89–134 87–131
HES pathway
Cost per patient Mean= 177 142 173
95% CI= 164–219 129–179 157–209
SDOCT surveillance vs. HES
pathway
Cost per patient Mean= −76 −41 −74
95% CI= −70 to −81 −37 to −46 −67 to −79
aUnder the HES pathway, once eyes were assessed at HES for the ﬁrst
time after diagnosis of R1M1 at screening they would no longer
require surveillance; bUnder both surveillance options, assuming that
there was no further surveillance for SDOCT negative results if the
clinic grading was R0M0 or R1M0
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effective but generates substantial cost savings. We found
that after the ﬁrst surveillance visit in an SD-OCT clinic,
less than 20% of patients required referral to HES as they
were found not to have macular oedema or CSMO and
could be safely monitored at an SD-OCT follow-up clinic or
discharged back to screening if no longer screen positive for
maculopathy.
At a cost of £110 and £87 for a ﬁrst and follow-up face-
to-face consultant visit, respectively, in ophthalmology, in
addition to £24 for SD-OCT imaging, the costs of assess-
ment at HES are considerable. By contrast, at a cost of £53 a
visit including SD-OCT imaging, the costs of an SD-OCT
surveillance clinic are signiﬁcantly lower. By reducing the
number of patients referred to HES without CSMO and
referring only those who will beneﬁt from doing so, the 1-
year cost savings associated with surveillance in an SD-
OCT clinic rather than HES was £76 (95% CI: 70–81), that
is. a saving of 41% compared with having all these eyes
assessed in HES.
Despite our study being based on a large number of eyes
diagnosed as R1M1 at screening, with individual patient
record linkage of data on DR screening appointments, SD-
OCT clinic surveillance visits, HES appointments and eye
treatments received, our study is not without limitations.
First, we assumed that surveillance in an SD-OCT clinic
would yield the same eye outcomes as surveillance in HES,
that is we assumed that the sensitivity of SD-OCT at
detecting CSMO would be equal to that of HES assessment.
Previous studies and literature reviews [16, 26], suggest that
SD-OCT performs very well with very similar outcomes.
Second, we only established the cost implications of the two
surveillance programmes over 1-year and not over the
longer-term, which would most likely have resulted in lar-
ger cost savings by reviewing patients who are screen
positive with R1M1 in digital surveillance clinics with SD-
OCT as opposed to HES.
Finally, with no control group to compare the SD-OCT
clinic surveillance programme with, we assumed that
instead of attending the SD-OCT clinic for surveillance,
patients attended HES directly and were then followed-up in
a similar fashion in HES to that observed in the Glouces-
tershire SD-OCT clinic surveillance programme. We tested
the implications of this assumption in our sensitivity ana-
lyses, which showed that even if eyes were assessed at HES
for the ﬁrst time after diagnosis of R1M1 at screening and
no longer required surveillance, the SD-OCT clinic pathway
still generated signiﬁcant cost savings.
In conclusion, our analysis shows that SD-OCT digital
surveillance of patients with diabetes, background diabetic
retinopathy (R1) and evidence of diabetic maculopathy
(M1) at DR screening is not only cost-effective but gen-
erates considerable cost savings.
Summary
What was known before:
● The NHS Diabetic Eye Screening Programme have
introduced digital surveillance clinics into their pathway
for those patients who, in the opinion of the Clinical
Lead, need more frequent review and do not require
referral to the HES.
What this study adds:
● This paper is the ﬁrst to show that the use of OCT in the
digital surveillance pathway of the English NHS
Diabetic Eye Screening Programme is both effective
and cost-effective.
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